Combined Inhibition of Bcl-2 and Mcl-1 Circumvents Resistance of TP53 Deficient/Mutant AML to BH3 Mimetics

被引：3

作者：

Carter, Bing Z. ^{[1
]}

Mak, Po Yee ^{[1
]}

Tao, Wenjing ^{[1
]}

Ostermann, Lauren B. ^{[1
]}

Boettcher, Steffen ^{[2
]}

Nishida, Yuki ^{[1
]}

Ayoub, Edward ^{[1
]}

Ruvolo, Vivian ^{[3
,4
]}

Jabbour, Elias J. ^{[3
]}

Hughes, Paul ^{[5
]}

Morrow, P. K. ^{[6
]}

Andreeff, Michael ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Sect Mol Hematol & Therapy, Houston, TX 77030 USA

[2] Univ & Univ Hosp Zurich, Med Oncol & Hematol, Zurich, Switzerland

[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Houston, TX 77030 USA

[5] Amgen Inc, Oncol Res, Thousand Oaks, CA 91320 USA

[6] Amgen Inc, Thousand Oaks, CA 91320 USA

来源：

关键词：

D O I：

10.1182/blood-2021-148014

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2239

引用

页数：4